J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers et al., Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, Int. J. Cancer, vol.136, pp.359-386, 2015.

F. Levi, J. Ferlay, C. Galeone, F. Lucchini, E. Negri et al., The changing pattern of kidney cancer incidence and mortality in Europe, BJU Int, vol.101, pp.949-958, 2008.

S. C. King, L. A. Pollack, J. Li, J. B. King, and V. A. Master, Continued increase in incidence of renal cell carcinoma, especially in young patients and high grade disease: United States, J. Urol, vol.191, pp.1665-1670, 2001.

H. Moch, A. L. Cubilla, P. A. Humphrey, V. E. Reuter, and T. M. Ulbright, The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours, Eur. Urol, vol.70, pp.93-105, 2016.

G. G. Malouf, E. Comperat, H. Yao, R. Mouawad, V. Lindner et al., Unique Transcriptomic Profile of Collecting Duct Carcinomas Relative to Upper Tract Urothelial Carcinomas and other Kidney Carcinomas, Sci. Rep, vol.6, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01357776

W. G. Kaelin and . Jr, The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma, Clin. Cancer Res, vol.13, issue.2, pp.680-684, 2007.

G. Banumathy and P. Cairns, Signaling pathways in renal cell carcinoma, Cancer Biol, vol.10, pp.658-664, 2010.

, Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma, Nature, vol.499, pp.43-49, 2013.

, Cancer Genome Atlas Research Network

W. M. Linehan, P. T. Spellman, C. J. Ricketts, C. J. Creighton, S. S. Fei et al., Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma, N. Engl. J. Med, vol.374, pp.135-145, 2016.

C. F. Davis, C. J. Ricketts, M. Wang, L. Yang, A. D. Cherniack et al., The somatic genomic landscape of chromophobe renal cell carcinoma, Cancer Cell, vol.26, pp.319-330, 2014.

P. Argani, MiT family translocation renal cell carcinoma, Semin. Diagn. Pathol, vol.32, pp.103-113, 2015.

G. G. Malouf, F. A. Monzon, J. Couturier, V. Molinie, B. Escudier et al., Genomic heterogeneity of translocation renal cell carcinoma, Clin. Cancer Res, vol.19, pp.4673-4684, 2013.

F. Chen, Y. Zhang, Y. Senbabaoglu, G. Ciriello, L. Yang et al., Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma, Cell. Rep, vol.14, pp.2476-2489, 2016.

M. B. Amin, S. C. Smith, A. Agaimy, P. Argani, E. M. Comperat et al., Collecting duct carcinoma versus renal medullary carcinoma: An appeal for nosologic and biological clarity, Am. J. Surg. Pathol, vol.38, pp.871-874, 2014.

J. R. Srigley, B. Delahunt, J. N. Eble, L. Egevad, J. I. Epstein et al., The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia, Am. J. Surg. Pathol, vol.37, pp.1469-1489, 2013.

S. K. Pal, T. K. Choueiri, K. Wang, D. Khaira, J. A. Karam et al., Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling, Eur. Urol, vol.70, pp.516-521, 2016.

K. E. Beckermann, D. Sharma, S. Chaturvedi, P. Msaouel, M. R. Abboud et al., Renal Medullary Carcinoma: Establishing Standards in Practice, J. Oncol. Pract, vol.13, pp.414-421, 2017.

M. I. Carlo, J. Chaim, S. Patil, Y. Kemel, A. M. Schram et al., Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes, Clin. Genitourin. Cancer, vol.15, pp.987-994, 2017.

G. G. Malouf, S. M. Ali, K. Wang, S. Balasubramanian, J. S. Ross et al., Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations, Eur. Urol, vol.70, pp.348-357, 2016.

T. F. Gajewski, H. Schreiber, and Y. X. Fu, Innate and adaptive immune cells in the tumor microenvironment, Nat. Immunol, vol.14, pp.1014-1022, 2013.

D. S. Chen and I. Mellman, Oncology meets immunology: The cancer-immunity cycle, Immunity, vol.39, pp.1-10, 2013.

T. A. Ferguson, J. Choi, and D. R. Green, Armed response: How dying cells influence T-cell functions, Immunol. Rev, vol.241, pp.77-88, 2011.

K. Franciszkiewicz, A. Boissonnas, M. Boutet, C. Combadiere, and F. Mami-chouaib, Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response, Cancer Res, vol.72, pp.6325-6332, 2012.

D. S. Chen, B. A. Irving, and F. S. Hodi, Molecular pathways: Next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1, Clin. Cancer Res, vol.18, pp.6580-6587, 2012.

D. I. Gabrilovich and S. Nagaraj, Myeloid-derived suppressor cells as regulators of the immune system, Nat. Rev. Immunol, vol.9, pp.162-174, 2009.

D. I. Gabrilovich, H. L. Chen, K. R. Girgis, H. T. Cunningham, G. M. Meny et al., Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells, Nat. Med, vol.2, pp.1096-1103, 1996.

D. Gabrilovich, T. Ishida, T. Oyama, S. Ran, V. Kravtsov et al., Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo, Blood, vol.92, pp.4150-4166, 1998.

A. T. Henze and M. Mazzone, The impact of hypoxia on tumor-associated macrophages, J. Clin. Investig, vol.126, pp.3672-3679, 2016.

A. Sica and M. Massarotti, Myeloid suppressor cells in cancer and autoimmunity, J. Autoimmun, vol.85, pp.117-125, 2017.

T. Voron, O. Colussi, E. Marcheteau, S. Pernot, M. Nizard et al., VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors, J. Exp. Med, vol.212, pp.139-148, 2015.

L. Tian, A. Goldstein, H. Wang, H. Ching-lo, I. Sun-kim et al., Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming, Nature, vol.544, pp.250-254, 2017.

B. Thienpont and D. Lambrechts, It's T Time for Normal Blood Vessels, Dev. Cell, vol.41, pp.125-126, 2017.

G. Fyfe, R. I. Fisher, S. A. Rosenberg, M. Sznol, D. R. Parkinson et al., Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy, J. Clin. Oncol, vol.13, pp.688-696, 1995.

S. Negrier, B. Escudier, C. Lasset, J. Y. Douillard, J. Savary et al., Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie, N. Engl. J. Med, vol.338, pp.1272-1278, 1998.

R. J. Motzer, B. Escudier, D. F. Mcdermott, S. George, H. J. Hammers et al., Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, N. Engl. J. Med, vol.373, pp.1803-1813, 2015.

H. J. Hammers, E. R. Plimack, J. R. Infante, B. I. Rini, D. F. Mcdermott et al., Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study, J. Clin. Oncol, vol.35, pp.3851-3858, 2017.

S. J. Antonia, J. A. Lopez-martin, J. Bendell, P. A. Ott, M. Taylor et al., Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial, Lancet Oncol, vol.17, pp.883-895, 2016.

J. Larkin, V. Chiarion-sileni, R. Gonzalez, J. J. Grob, C. L. Cowey et al., Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, N. Engl. J. Med, vol.373, pp.23-34, 2015.

R. J. Motzer, N. M. Tannir, D. F. Mcdermott, O. .;-aren-frontera, B. Melichar et al., Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma, N. Engl. J. Med, vol.378, pp.1277-1290, 2018.

G. Xie, D. Gu, L. Zhang, S. Chen, and D. Wu, A rapid and systemic complete response to stereotactic body radiation therapy and pembrolizumab in a patient with metastatic renal cell carcinoma, Cancer Biol, vol.18, pp.547-551, 2017.

V. S. Koshkin, P. C. Barata, T. Zhang, D. J. George, M. B. Atkins et al., Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma, J. Immunother. Cancer, vol.6, issue.9, 2018.

A. Amin, E. R. Plimack, M. S. Ernstoff, L. D. Lewis, T. M. Bauer et al., Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: The CheckMate 016 study, J. Immunother. Cancer, vol.6, 2018.

D. F. Mcdermott, M. A. Huseni, M. B. Atkins, R. J. Motzer, B. I. Rini et al., Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma, Nat. Med, vol.24, pp.749-757, 2018.

H. Akaza and T. Fukuyama, Axitinib for the treatment of advanced renal cell carcinoma, Expert Opin. Pharm, vol.15, pp.283-297, 2014.

T. K. Choueiri, J. Larkin, M. Oya, F. Thistlethwaite, M. Martignoni et al., Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): An open-label, dose-finding and dose-expansion, phase 1b trial, Lancet Oncol, vol.19, pp.451-460, 2018.

R. J. Motzer, K. Penkov, J. Haanen, B. Rini, L. Albiges et al., Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma, N. Engl. J. Med, vol.380, pp.1103-1115, 2019.

B. I. Rini, E. R. Plimack, V. Stus, R. Gafanov, R. Hawkins et al., Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma, N. Engl. J. Med, vol.380, pp.1116-1127, 2019.

E. A. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent et al., New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), Eur. J. Cancer, vol.45, pp.228-247, 2009.

D. Velasco, G. Krajewski, K. M. Albiges, L. Awad, M. M. Bellmunt et al., Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma, Cancer Immunol. Res, vol.4, pp.12-17, 2016.

L. Seymour, J. Bogaerts, A. Perrone, R. Ford, L. H. Schwartz et al., Guidelines for response criteria for use in trials testing immunotherapeutics, Lancet Oncol, vol.18, pp.143-152, 2017.

F. S. Hodi, M. Ballinger, B. Lyons, J. C. Soria, M. Nishino et al., Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy, J. Clin. Oncol, vol.36, pp.850-858, 2018.

L. Lay, J. Jarraya, H. Lebellec, L. Penel, and N. , The devil is in the details, Ann. Oncol, vol.28, pp.1676-1678, 2017.

J. D. Wolchok, A. Hoos, S. O'day, J. S. Weber, O. Hamid et al., Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria, Clin. Cancer Res, vol.15, pp.7412-7420, 2009.

J. C. Pignon, O. Jegede, S. A. Shukla, D. A. Braun, C. E. Horak et al., irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial, Clin. Cancer Res, 2019.

F. Erlmeier, W. Weichert, A. J. Schrader, M. Autenrieth, A. Hartmann et al., Prognostic impact of PD-1 and its ligands in renal cell carcinoma, vol.34, p.99, 2017.

M. S. Tsao, K. M. Kerr, M. Kockx, M. B. Beasley, A. C. Borczuk et al., PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project, J. Thorac. Oncol, vol.13, pp.1302-1311, 2018.

A. Basu, J. H. Yearley, L. Annamalai, C. Pryzbycin, and B. Rini, Association of PD-L1, PD-L2, and Immune Response Markers in Matched Renal Clear Cell Carcinoma Primary and Metastatic Tissue Specimens, Am. J. Clin. Pathol, vol.151, pp.217-225, 2019.

J. I. Lopez, R. Pulido, J. M. Cortes, J. C. Angulo, and C. H. Lawrie, Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy, Pathol. Res. Pract, vol.214, pp.1110-1114, 2018.

X. H. He, L. H. Xu, and Y. Liu, Identification of a novel splice variant of human PD-L1 mRNA encoding an isoform-lacking Igv-like domain, Acta Pharm. Sin, vol.26, pp.462-468, 2005.

J. Cogswell, H. D. Inzunza, Q. Wu, J. N. Feder, G. Mintier et al., An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1, Mol. Diagn, vol.21, pp.85-93, 2017.

K. S. Kim, R. R. Sekar, D. Patil, M. A. Dimarco, H. T. Kissick et al., Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma

S. J. Shin, Y. K. Jeon, P. J. Kim, Y. M. Cho, J. Koh et al., Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status, Ann. Surg. Oncol, vol.23, pp.694-702, 2016.

S. F. Kammerer-jacquet, S. Medane, K. Bensalah, J. C. Bernhard, M. Yacoub et al., Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy, Target Oncol, vol.12, pp.487-494, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01578072

A. A. Lalani, K. P. Gray, L. Albiges, M. Callea, J. C. Pignon et al., Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression, Oncotarget, vol.8, pp.103428-103436, 2017.

T. K. Choueiri, A. P. Fay, K. P. Gray, M. Callea, T. H. Ho et al., PD-L1 expression in nonclear-cell renal cell carcinoma, Ann. Oncol, vol.25, pp.2178-2184, 2014.

B. Beuselinck, S. Job, E. Becht, A. Karadimou, V. Verkarre et al., Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting, Clin. Cancer Res, vol.21, pp.1329-1339, 2015.

A. A. Hakimi, M. H. Voss, F. Kuo, A. Sanchez, M. Liu et al., Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear cell Renal Cell Cancer-Data from a Randomized Phase III Trial. Cancer Discov, 2019.

M. Yarchoan, A. Hopkins, and E. M. Jaffee, Tumor Mutational Burden and Response Rate to PD-1 Inhibition, N. Engl. J. Med, vol.377, pp.2500-2501, 2017.

D. Velasco, G. Miao, D. Voss, M. H. Hakimi, A. A. Hsieh et al., Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups, Cancer Immunol. Res, vol.4, pp.820-822, 2016.

L. B. Alexandrov, S. Nik-zainal, D. C. Wedge, S. A. Aparicio, S. Behjati et al., Signatures of mutational processes in human cancer, Nature, vol.500, pp.415-421, 2013.

S. Turajlic, K. Litchfield, H. Xu, R. Rosenthal, N. Mcgranahan et al., Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: A pan-cancer analysis, Lancet Oncol, vol.18, pp.1009-1021, 2017.